|
Abstract:
|
In randomized oncology trials, patients in the control arm are sometimes permitted to switch to receive experimental drug after disease progression. This is mainly due to ethical reasons or to reduce the patient dropout rate. While progression?free survival is not usually impacted by crossover, the treatment effect on overall survival can be highly confounded. The rank?preserving structural failure time (RPSFT) model is one of the most widely used model. In this presentation, we compare the performance of RPSFT and other competing methods for correcting the impact of treatment switching on overall survival.
|
